We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bullous pemphigoid associated with Grover disease: a specific toxicity of anti‐PD‐1 therapies?
- Authors
Jendoubi, Fatma; Sibaud, Vincent; Meyer, Nicolas; Tournier, Emilie; Fortenfant, Françoise; Livideanu, Cristina Bulai; Paul, Carle; Konstantinou, Maria‐Polina
- Abstract
Bullous pemphigoid associated with Grover disease: a specific toxicity of anti-PD-1 therapies? Cutaneous adverse events (AE) appear to be their most prevalent toxicity.1 Immunotherapy-induced bullous pemphigoid (BP) affects roughly 1% of patients exposed to anti-PD-1.1 Also, Grover disease (GD) has been sporadically described under this treatment.1 We herein report two cases of patients treated with anti-PD-1 therapy who developed features of both BP and GD concomitantly. Anti-programmed death 1 (PD-1) are monoclonal antibodies approved for the treatment of metastatic melanoma and other malignancies.
- Subjects
BULLOUS pemphigoid; IMMUNE checkpoint inhibitors; CANCER cells
- Publication
International Journal of Dermatology, 2022, Vol 61, Issue 6, pe200
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16068